-
Something wrong with this record ?
Analysis of chronic myeloid leukaemia during deep molecular response by genomic PCR: a traffic light stratification model with impact on treatment-free remission
K. Machova Polakova, H. Zizkova, J. Zuna, E. Motlova, L. Hovorkova, A. Gottschalk, I. Glauche, J. Koblihova, P. Pecherkova, H. Klamova, M. Stastna Markova, D. Srbova, A. Benesova, V. Polivkova, T. Jurcek, D. Zackova, J. Mayer, T. Ernst, FX....
Language English Country Great Britain
Document type Journal Article, Research Support, Non-U.S. Gov't
Grant support
NV16-30186A
MZ0
CEP Register
Digital library NLK
Full text - Article
NLK
ProQuest Central
from 2000-01-01 to 1 year ago
Open Access Digital Library
from 1997-01-01
Nursing & Allied Health Database (ProQuest)
from 2000-01-01 to 1 year ago
Health & Medicine (ProQuest)
from 2000-01-01 to 1 year ago
Public Health Database (ProQuest)
from 2000-01-01 to 1 year ago
- MeSH
- Fusion Proteins, bcr-abl genetics MeSH
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive drug therapy genetics mortality MeSH
- Adult MeSH
- Remission Induction MeSH
- Protein Kinase Inhibitors therapeutic use MeSH
- Middle Aged MeSH
- Humans MeSH
- RNA, Messenger analysis MeSH
- Withholding Treatment MeSH
- Polymerase Chain Reaction methods MeSH
- Neoplasm, Residual MeSH
- Aged MeSH
- Protein-Tyrosine Kinases antagonists & inhibitors MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
This work investigated patient-specific genomic BCR-ABL1 fusions as markers of measurable residual disease (MRD) in chronic myeloid leukaemia, with a focus on relevance to treatment-free remission (TFR) after achievement of deep molecular response (DMR) on tyrosine kinase inhibitor (TKI) therapy. DNA and mRNA BCR-ABL1 measurements by qPCR were compared in 2189 samples (129 patients) and by digital PCR in 1279 sample (62 patients). A high correlation was found at levels of disease above MR4, but there was a poor correlation for samples during DMR. A combination of DNA and RNA MRD measurements resulted in a better prediction of molecular relapse-free survival (MRFS) after TKI stop (n = 17) or scheduled interruption (n = 25). At 18 months after treatment cessation, patients with stopped or interrupted TKI therapy who were DNA negative/RNA negative during DMR maintenance (green group) had an MRFS of 80% and 100%, respectively, compared with those who were DNA positive/RNA negative (MRFS = 57% and 67%, respectively; yellow group) or DNA positive/RNA positive (MRFS = 20% for both cohorts; red group). Thus, we propose a "traffic light" stratification as a TFR predictor based on DNA and mRNA BCR-ABL1 measurements during DMR maintenance before TKI cessation.
Abteilung Hämatologie Onkologie Klinik für Innere Medizin 2 University of Jena Jena Germany
BERGONIE Institute BORDEAUX INSERM U1218 University of Bordeaux Bordeaux France
Institute for Medical Informatics and Biometry Partner Site Dresden Dresden Germany
Institute of Hematology and Blood Transfusion Prague Czech Republic
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc20027980
- 003
- CZ-PrNML
- 005
- 20231102133250.0
- 007
- ta
- 008
- 210105s2020 xxk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1038/s41375-020-0882-1 $2 doi
- 035 __
- $a (PubMed)32472084
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Machova Polakova, Katerina $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic. katerina.machova@uhkt.cz. Institute of Pathological Physiology, First Faculty of Medicine, Charles University, Prague, Czech Republic. katerina.machova@uhkt.cz.
- 245 10
- $a Analysis of chronic myeloid leukaemia during deep molecular response by genomic PCR: a traffic light stratification model with impact on treatment-free remission / $c K. Machova Polakova, H. Zizkova, J. Zuna, E. Motlova, L. Hovorkova, A. Gottschalk, I. Glauche, J. Koblihova, P. Pecherkova, H. Klamova, M. Stastna Markova, D. Srbova, A. Benesova, V. Polivkova, T. Jurcek, D. Zackova, J. Mayer, T. Ernst, FX. Mahon, S. Saussele, I. Roeder, NCP. Cross, A. Hochhaus,
- 520 9_
- $a This work investigated patient-specific genomic BCR-ABL1 fusions as markers of measurable residual disease (MRD) in chronic myeloid leukaemia, with a focus on relevance to treatment-free remission (TFR) after achievement of deep molecular response (DMR) on tyrosine kinase inhibitor (TKI) therapy. DNA and mRNA BCR-ABL1 measurements by qPCR were compared in 2189 samples (129 patients) and by digital PCR in 1279 sample (62 patients). A high correlation was found at levels of disease above MR4, but there was a poor correlation for samples during DMR. A combination of DNA and RNA MRD measurements resulted in a better prediction of molecular relapse-free survival (MRFS) after TKI stop (n = 17) or scheduled interruption (n = 25). At 18 months after treatment cessation, patients with stopped or interrupted TKI therapy who were DNA negative/RNA negative during DMR maintenance (green group) had an MRFS of 80% and 100%, respectively, compared with those who were DNA positive/RNA negative (MRFS = 57% and 67%, respectively; yellow group) or DNA positive/RNA positive (MRFS = 20% for both cohorts; red group). Thus, we propose a "traffic light" stratification as a TFR predictor based on DNA and mRNA BCR-ABL1 measurements during DMR maintenance before TKI cessation.
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a bcr-abl fúzové proteiny $x genetika $7 D016044
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a chronická myeloidní leukemie $x farmakoterapie $x genetika $x mortalita $7 D015464
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a reziduální nádor $7 D018365
- 650 _2
- $a polymerázová řetězová reakce $x metody $7 D016133
- 650 _2
- $a inhibitory proteinkinas $x terapeutické užití $7 D047428
- 650 _2
- $a tyrosinkinasy $x antagonisté a inhibitory $7 D011505
- 650 _2
- $a messenger RNA $x analýza $7 D012333
- 650 _2
- $a indukce remise $7 D012074
- 650 _2
- $a nenasazení léčby $7 D028761
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Zizkova, Hana $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic.
- 700 1_
- $a Zuna, Jan $u CLIP, Department of Paediatric Haematology and Oncology, Second Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic.
- 700 1_
- $a Motlova, Eliska $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic.
- 700 1_
- $a Hovorkova, Lenka $u CLIP, Department of Paediatric Haematology and Oncology, Second Faculty of Medicine, Charles University and University Hospital Motol, Prague, Czech Republic.
- 700 1_
- $a Gottschalk, Andrea $u Institute for Medical Informatics and Biometry (IMB), Carl Gustav Carus Faculty of Medicine, TU Dresden, Dresden, Germany.
- 700 1_
- $a Glauche, Ingmar $u Institute for Medical Informatics and Biometry (IMB), Carl Gustav Carus Faculty of Medicine, TU Dresden, Dresden, Germany.
- 700 1_
- $a Koblihova, Jitka $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic.
- 700 1_
- $a Pecherková, Pavla, $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic. $d 1980- $7 ctu2013787641
- 700 1_
- $a Klamova, Hana $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic. Institute of Clinical and Experimental Hematology, First Faculty of Medicine, Charles University, Prague, Czech Republic.
- 700 1_
- $a Stastna Markova, Marketa $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic. Institute of Clinical and Experimental Hematology, First Faculty of Medicine, Charles University, Prague, Czech Republic.
- 700 1_
- $a Srbova, Dana $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic.
- 700 1_
- $a Benesova, Adela $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic.
- 700 1_
- $a Polivkova, Vaclava $u Institute of Hematology and Blood Transfusion, Prague, Czech Republic.
- 700 1_
- $a Jurcek, Tomas $u Center of Molecular Biology and Gene Therapy, Internal Hematology and Oncology Clinic, Faculty Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic.
- 700 1_
- $a Zackova, Daniela $u Internal Hematology and Oncology Clinic, Faculty Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic.
- 700 1_
- $a Mayer, Jiri $u Internal Hematology and Oncology Clinic, Faculty Hospital Brno and Faculty of Medicine, Masaryk University, Brno, Czech Republic.
- 700 1_
- $a Ernst, Thomas $u Abteilung Hämatologie/Onkologie, Klinik für Innere Medizin II, University of Jena, Jena, Germany.
- 700 1_
- $a Mahon, Francois X $u BERGONIE Institute BORDEAUX, INSERM U1218 University of Bordeaux, Bordeaux, France.
- 700 1_
- $a Saussele, Susanne $u Department of Haematology and Oncology, University Hospital Mannheim, Heidelberg University, Mannheim, Germany.
- 700 1_
- $a Roeder, Ingo $u Institute for Medical Informatics and Biometry (IMB), Carl Gustav Carus Faculty of Medicine, TU Dresden, Dresden, Germany. National Center for Tumor Diseases (NCT), Partner Site Dresden, Dresden, Germany.
- 700 1_
- $a Cross, Nicholas C P $u Wessex Regional Genetics Laboratory, Salisbury NHS Foundation Trust, Salisbury and Faculty of Medicine, University of Southampton, Southampton, UK.
- 700 1_
- $a Hochhaus, Andreas $u Abteilung Hämatologie/Onkologie, Klinik für Innere Medizin II, University of Jena, Jena, Germany.
- 773 0_
- $w MED00003138 $t Leukemia $x 1476-5551 $g Roč. 34, č. 8 (2020), s. 2113-2124
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/32472084 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20210105 $b ABA008
- 991 __
- $a 20231102133244 $b ABA008
- 999 __
- $a ok $b bmc $g 1608315 $s 1119160
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2020 $b 34 $c 8 $d 2113-2124 $e 20200529 $i 1476-5551 $m Leukemia $n Leukemia $x MED00003138
- GRA __
- $a NV16-30186A $p MZ0
- LZP __
- $a Pubmed-20210105
